Dr. Hamish Cameron has joined SV Life Sciences as a venture partner. He previously was CEO of Cambridge Antibody Technology, following its 2006 acquisition by Astra Zeneca.
SV Life Sciences (“SVLS”) today announced the appointment of Dr. Hamish Cameron as Venture Partner. Dr. Cameron will be focused on therapeutic investments in Europe and the
“Dr. Cameron is one of the best qualified, effective and commercially astute medics that we know,” said Kate Bingham, SVLS Managing Partner, specializing in therapeutic investments. “He has worked in a range of clinical areas at Astra Zeneca and his recent leadership of Cambridge Antibody Technology (“CAT”) as Chief Executive Officer will prove invaluable to building and growing successful new therapeutic companies.”
Before joining SVLS, Dr. Cameron was appointed CEO of Cambridge Antibody Technology (“CAT”), following its acquisition by Astra Zeneca in 2006. Prior to that, he held a series of senior positions at Astra Zeneca including Head of the Cardiovascular Therapy Area, Global Head of Medical Research and member of the R&D Leadership Team. Dr. Cameron started his industry career with Janssen, after working as a physician in the
About SV Life Sciences
SV Life Sciences Advisers, LLC (“SVLS”) is a life sciences-focused venture capital business. SVLS funds invest in companies requiring funding within the human life sciences sector including biotechnology and pharmaceuticals, medical devices and instruments, healthcare IT and services. SVLS advises or manages four venture capital funds and a publicly traded investment trust with total capital of approximately $1.6 billion that invest in life sciences companies at all stages of development. SVLS has 29 professionals and has invested in over 175 companies over the course of the last decade making SVLS one of the largest and most active healthcare investors in the world. SVLS was established in 1993 and currently has offices in